Estimating long-term outcomes in classic Hodgkin lymphoma: a United States population-based oncology simulation model based on overall survival from the ECHELON-1 trial Tycel Phillips, Kristen Migliaccio-Walle, Kristina S. Yu, Brian Bloudek, Nicholas Liu, Michelle Fanale & show all Pages...
EE501 Comparison of Survival Extrapolations Using Early Vs Late Data Cuts from the Echelon-1 Trial in Frontline Advanced Hodgkin Lymphomadoi:10.1016/j.jval.2023.03.2480S. LiM. MittalD. ZouV. PalyValue in Health
The safety profile in pts treated with A+AVD showed no new safety signals at 7 years.Clinical trial information: NCT01712490.7-year OS rates by subgroup (ITT).Group, % (95% CI)A+AVDOS Rate, % (95% CI)n=664ABVDOS Rate, % (95% CI)n=670HR (95% CI)p-valueAll pts93.5 (91.1–...
The global, phase III ECHELON-1 trial compared brentuximab vedotin (BV), a CD30-directed antibody-drug conjugate, in combination with doxorubicin, vinblastine, and dacarbazine (A+AVD) versus ABVD.1 cHL is most commonly diagnosed in adolescents and young adults (AYA),2 , 3 defined by the ...
PS1070 THE ECHELON-2 TRIAL: RESULTS OF A RANDOMIZED, DOUBLE-BLIND PHASE 3 STUDY OF BRENTUXIMAB VEDOTIN AND CHP (A+CHP) VERSUS CHOP IN FRONTLINE TREATMENT OF PATIENTS WITH CD30+ PERIPHERAL T-CELL LYMPHOMASdoi:10.1097/01.HS9.0000562572.63485.4fIllidge, T....